April 25, 2024
Astellas Pharma’s androgen receptor signaling inhibitor Xtandi (enzalutamide) grabbed the official stamp of approval in Europe for its label expansion for the earlier treatment of certain patients with prostate cancer. The European Commission approved the drug on April 22 as...read more